NCT04090970Unknown不适用
Briagen™ Case Study and Observation of Skin Excision Healing in Mohs and Other Dermatological Procedures
Gemstone Biotherapeutics2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2019年8月26日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- Healing Time
研究概览
简要总结
This research study is evaluating a study product called Briagen™ as a possible treatment for wound healing after Mohs procedure.
详细描述
Briagen, the study product being used in this study, is a natural complex carbohydrate wound dressing for skin wounds created by Mohs surgery.
Briagen was developed with the intent to improve healing time and reduce scarring of skin wounds. Briagen seeks to match the mechanical aspects of your skin (thickness, stiffness, hydration, pore size) to assist in the healing process.
The purpose of this research study is to observe healing time of Briagen applied to wounds created as a result of Mohs surgery.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient seeking treatment for wound created by Mohs or other full thickness skin excisions
- •Over 18 years of age
- •English-speaking
- •Presents for treatment within 24 hours of initial Mohs skin excision procedure.
排除标准
- •History of significant wound complications and non-compliance on wound maintenance instructions (infections, disturbing the wound during the healing process, etc.)
- •Known diagnosis of Diabetes
- •Active infection in the wound bed
- •Under 18 years of age
结局指标
主要结局
Healing Time
时间窗: 28 days
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
DERMALIX Efficacy on Diabetic Foot UlcersDiabetic FootDiabetic Foot UlcerNCT03136822Dermis Pharma48
已完成
不适用
Investigation of the Clinical Performance of Biatain Fiber Ag on BurnsPartial-thickness BurnNCT05824026Coloplast A/S52
已完成
不适用
Investigation of the Clinical Performance of Biatain Fiber Ag on Venous Leg UlcersVenous Leg UlcerNCT05873257Coloplast A/S50
已完成
3 期
Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEBDystrophic Epidermolysis BullosaRecessive Dystrophic Epidermolysis BullosaDominant Dystrophic Epidermolysis BullosaNCT04491604Krystal Biotech, Inc.31
已完成
1 期
Treatment of Cutaneous Ulcers With a Novel Biological DressingVenous UlcersNCT00207818CHU de Quebec-Universite Laval6